Zevalin (ibritumomab tiuxetan) is an antibody pharmaceutical. Ibritumomab tiuxetan was first approved as Zevalin on 2002-02-19. It is used to treat b-cell lymphoma and follicular lymphoma in the USA. It has been approved in Europe to treat follicular lymphoma. The pharmaceutical is active against B-lymphocyte antigen CD20.
|Common Name||Ibritumomab tiuxetan|
|Indication||b-cell lymphoma, follicular lymphoma|
|Drug Class||Monoclonal antibodies; chelating agents|